SCHEMBL257699

SCHEMBL257699

COc1ccc(-c2c(C)nn3c(-c4ccccc4)cc(=O)[nH]c23)cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.60
MAPK1 P28482 2/20 0.60
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
PLAT P00750 6/20 0.48
TDP1 Q9NUW8 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 1/20 0.44
HPGD P15428 1/20 0.44
EGFR P00533 1/20 0.44
MEN1 O00255 1/20 0.43
STAT1 P42224 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020584 0.90 PLAT (0.48) MAPTMAPK1PLAT
SCHEMBL257402 0.88 NPC1 (0.46) MAPTMAPK1NPC1RAB9APLAT
SCHEMBL10072288 0.85 MAPT (0.50) MAPTMAPK1PLATTDP1CYP1A2
SCHEMBL16556559 0.85 PLAT (0.47) MAPTMAPK1PLATTDP1CYP1A2
SCHEMBL256819 0.85 PLAT (0.64) MAPTMAPK1PLATCYP1A2
SCHEMBL1614079 0.81 MAPT (0.51) MAPTMAPK1NPC1RAB9ATDP1
SCHEMBL13516076 0.81 MAPT (0.51) MAPTMAPK1NPC1RAB9ATDP1
SCHEMBL257296 0.79 PLAT (0.53) NPC1RAB9APLATHPGD
SCHEMBL10072102 0.78 PLAT (0.46) MAPTMAPK1NPC1RAB9APLAT
SCHEMBL256944 0.77 PLAT (0.51) NPC1RAB9APLATHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 MAPT 2617/4885MAPK1 519/4885NPC1 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.